Last reviewed · How we verify

Placebo in combination with nivolumab

HUYABIO International, LLC. · Phase 3 active Small molecule

Placebo in combination with nivolumab is a PD-1 inhibitor Small molecule drug developed by HUYABIO International, LLC.. It is currently in Phase 3 development for Metastatic non-small cell lung cancer, PD-L1 positive, Metastatic renal cell carcinoma, Adenocarcinoma of the bladder. Also known as: For nivolumab: OPDIVO®.

Nivolumab is a PD-1 inhibitor that works by blocking the PD-1 receptor on T cells, allowing them to attack cancer cells.

Nivolumab is a PD-1 inhibitor that works by blocking the PD-1 receptor on T cells, allowing them to attack cancer cells. Used for Metastatic non-small cell lung cancer, PD-L1 positive, Metastatic renal cell carcinoma, Adenocarcinoma of the bladder.

At a glance

Generic namePlacebo in combination with nivolumab
Also known asFor nivolumab: OPDIVO®
SponsorHUYABIO International, LLC.
Drug classPD-1 inhibitor
TargetPD-1
ModalitySmall molecule
Therapeutic areaOncology
PhasePhase 3

Mechanism of action

By blocking the PD-1 receptor, nivolumab allows T cells to recognize and attack cancer cells, leading to an immune response against the tumor. This mechanism is particularly effective in treating cancers with high PD-L1 expression.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Placebo in combination with nivolumab

What is Placebo in combination with nivolumab?

Placebo in combination with nivolumab is a PD-1 inhibitor drug developed by HUYABIO International, LLC., indicated for Metastatic non-small cell lung cancer, PD-L1 positive, Metastatic renal cell carcinoma, Adenocarcinoma of the bladder.

How does Placebo in combination with nivolumab work?

Nivolumab is a PD-1 inhibitor that works by blocking the PD-1 receptor on T cells, allowing them to attack cancer cells.

What is Placebo in combination with nivolumab used for?

Placebo in combination with nivolumab is indicated for Metastatic non-small cell lung cancer, PD-L1 positive, Metastatic renal cell carcinoma, Adenocarcinoma of the bladder, Adenocarcinoma of the esophagus, Adenocarcinoma of the gastroesophageal junction.

Who makes Placebo in combination with nivolumab?

Placebo in combination with nivolumab is developed by HUYABIO International, LLC. (see full HUYABIO International, LLC. pipeline at /company/huyabio-international-llc).

Is Placebo in combination with nivolumab also known as anything else?

Placebo in combination with nivolumab is also known as For nivolumab: OPDIVO®.

What drug class is Placebo in combination with nivolumab in?

Placebo in combination with nivolumab belongs to the PD-1 inhibitor class. See all PD-1 inhibitor drugs at /class/pd-1-inhibitor.

What development phase is Placebo in combination with nivolumab in?

Placebo in combination with nivolumab is in Phase 3.

What are the side effects of Placebo in combination with nivolumab?

Common side effects of Placebo in combination with nivolumab include Fatigue, Diarrhea, Nausea, Rash, Pruritus, Hypothyroidism.

What does Placebo in combination with nivolumab target?

Placebo in combination with nivolumab targets PD-1 and is a PD-1 inhibitor.

Related